EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2

Virginia Fuochi, Salvatore Furnari, Giuseppe Floresta, Vincenzo Patamia, Chiara Zagni, Filippo Drago, Antonio Rescifina, Pio Maria Furneri

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.202400545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Virginia Fuochi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Biotechnological Sciences (Biometec), University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Enoxaparin, Heparan Sulfate, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Techdow Pharma Italy S.r.l., NextGeneration EU-MUR PNRR Extended Partnership on Emerging Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the world transitions from the acute phase of the COVID‐19 pandemic caused by SARS‐CoV‐2, the scientific community continues to explore various therapeutic avenues to control its spread and mitigate its ongoing effects. Among the promising candidates are heparan sulfate (HS) and enoxaparin (EX), which have emerged as potential virus inhibitors. HS, a type of glycosaminoglycan, plays a prominent role in the attachment of the virus to host cells. At the same time, EX, a low‐molecular‐weight heparin, is being investigated for its ability to disrupt the interaction between the spike protein of SARS‐CoV‐2 and the ACE2 receptor in human cells. Understanding the mechanisms through which these substances operate could lay the foundation for new strategies in the ongoing management of COVID‐19. This study aimed to examine the details of SARS‐CoV‐2's entry mechanisms and the role of HS in this process. Furthermore, it examines EX's mechanism of action, highlighting how it potentially inhibits SARS‐CoV‐2. The interactions between HS and the virus, alongside in‐vitro and in‐silico inhibition studies with HS and EX, are critically analyzed to assess their antiviral efficacy. Additionally, the antiviral activity of sulfated polysaccharides and the potential therapeutic applications of these findings are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinHeparan SulfateSARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentHumansCOVID-19Virus InternalizationSpike Glycoprotein, CoronavirusMolecular Docking SimulationAngiotensin-Converting Enzyme 2

Stichwörter der Autor:innen

ACE2SARS‐CoV‐2absorption inhibitionglycosaminoglycansmolecular docking

Substanzen

EnoxaparinHeparan SulfateAntiviral AgentsSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2spike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Biomedical and Biotechnological Sciences (Biometec), University of Catania, Catania, Italy.
  • Department of Drug and Health Sciences (DSFS), University of Catania, Catania, Italy.

Förderung

  • Techdow Pharma Italy S.r.l.
  • NextGeneration EU-MUR PNRR Extended Partnership on Emerging Infectious Diseases

Zitieren

APA

Fuochi, V., Furnari, S., Floresta, G., Patamia, V., Zagni, C., Drago, F., Rescifina, A., & Furneri, P. M. (2025). Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400545

Vancouver

Fuochi V, Furnari S, Floresta G, Patamia V, Zagni C, Drago F, et al. Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400545

BibTeX
@article{Fuochi2025,
  author = {Fuochi, Virginia and Furnari, Salvatore and Floresta, Giuseppe and Patamia, Vincenzo and Zagni, Chiara and Drago, Filippo and Rescifina, Antonio and Furneri, Pio Maria},
  title = {Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.202400545}
}
Kostenlos starten →